The goal is to profile RUNX2 and CBFB binding sites in an osteosarcoma cell line, SAOS2. Overall design: Fifty million of SAOS2 cells were fixed and subjected to ChIP-seq assay using RUNX2 or CBFB spe
In osteosarcoma patients, the development of metastases, often to the lungs, is the most frequent cause of death. To improve this situation, a deeper understanding of the molecular mechanisms governin
